Cyberonics publishes depression data
This article was originally published in The Gray Sheet
Results from the firm's pivotal and companion studies are published in the journal Biological Psychiatry, aiding the firm's quest to secure reimbursement for VNS Therapy for treatment-resistant depression. The articles represent the same data used to support the firm's PMA submission for the device, including the firm's 235-patient, 21-site pivotal D-02 study. The firm believes that reimbursement will be in place for the therapy by 2007 (1"The Gray Sheet" July 25, 2005, p. 17)...
You may also be interested in...
Cyberonics predicts reimbursement for VNS Therapy for treatment-resistant depression (TRD) will be fully secured by 2007, despite encountering protracted difficulties in gaining FDA approval
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.